John Kapeghian is Sr. Vice President and Global Head of Safety Evaluation & Toxicology for Frontage Laboratories, Inc. Prior to joining Frontage, Dr. Kapeghian was an independent consultant (Preclinical Safety Associates, LLC) specializing in toxicology and drug safety. He was formerly head of Charles River’s Navigator Scientific and Regulatory Consulting group, and held senior management positions at Sierra Biomedical, a contract laboratory subsequently acquired by Charles River. Dr. Kapeghian previously worked for Ciba Pharmaceuticals (now Novartis), heading up regulatory toxicology units and directing their U.S. Experimental Toxicology program. He received his Ph.D. in pharmacology/toxicology from the of ( campus) and has been board-certified in general toxicology by the American Board of Toxicology since 1985. John is a member of the of Toxicology (ACT), and Society of Toxicology (SOT). He formerly chaired the Pharmaceuticals Manufacturing Association’s DRUSAFE committee on In Vitro Toxicology and also served as a Section Editor for the International Journal of Toxicology from 1988 - 2008. John has experience in drug-induced mechanisms of liver toxicity and comparative metabolism, genotoxicity, and in small molecule, peptide/protein, antisense oligonucleotide, and biologics development, as well as in expert review of medical device safety. He has worked on regulatory applications for the U.S., Canada, Europe, Australia, and India, and has roughly 40 years of experience, with numerous publications and scientific presentations in the field.